Lassa Virus Countermeasures
Curr Top Microbiol Immunol. 2022 Oct 18. doi: 10.1007/82_2022_261. Online ahead of print.ABSTRACTLassa Fever (LF) is a viral hemorrhagic fever endemic in West Africa. LF begins with flu-like symptoms that are difficult to distinguish from other common endemic diseases such as malaria, dengue, and yellow fever making it hard to diagnose clinically. Availability of a rapid diagnostic test and other serological and molecular assays facilitates accurate diagnosis of LF. Lassa virus therapeutics are currently in different stages of preclinical development. Arevirumab, a cocktail of monoclonal antibodies, demonstrates a great safety and efficacy profile in non-human primates. Major efforts have been made in the development of a Lassa virus vaccine. Two vaccine candidates, MeV-NP and pLASV-GPC are undergoing evaluation in phase I clinical trials.PMID:36253593 | DOI:10.1007/82_2022_261
Source: Current Topics in Microbiology and Immunology - Category: Microbiology Authors: Lilia I Melnik Source Type: research
More News: African Health | Allergy & Immunology | Clinical Trials | Dengue Fever | Endemics | Lassa Fever | Malaria | Malaria Vaccine | Microbiology | Vaccines | Yellow Fever | Yellow Fever Vaccination